
The researchers searched English and Chinese databases comprehensively and summarized the epidemiological studies of non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) in China. They found that the prevalence of NAFLD in China is nearly 30% of the general population, which is twice as high as that in western countries, and it is the leading cause of chronic liver disease. The prevalence varies among provinces/regions, age groups, sexes, and individuals with different metabolic profiles. They also noted that many Chinese patients with chronic hepatitis B also have NAFLD. This review highlights Chinese scholars' efforts to achieve optimal disease management, including lifestyle interventions, antidiabetic drugs, traditional Chinese medicines, and innovative targeted therapies developed in China.
Like
Save
Share